NAFLD: patient identification strategies

In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

The Alzheimer’s disease drug development landscape

Hosted by: Julius Clinical. Speakers: Pieter van Bokhoven | CSO| IAO Amsterdam Neuroscience AUMC Jort Vijverberg | Neurologist | Amsterdam Neuroscience AUMC Topics that are discussed during this webinar: All major trends in Alzh...

Speakers: Dr. Jort Vijverberg

Public health and policy responses to NAFLD/NASH

Topics that has been discussed: The Impact of NAFLD/NASH What is being done to tackle NAFLD/NASH globally and nationally What still needs to be done in the fight against NAFLD/NASH How can you/your country advance the battle against ...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

Genetic architecture of NAFLD: where do we stand?

Genome-wide association studies have uncovered robust and reproducible associations between several genetic variations and the natural history of NAFLD. During this webinar, Professor Eric Trépo reviewed these findings that have provided compelli...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.
  • Webinars
  • Infectious Diseases & Vaccines, Vaccines

COVID-19 lessons from pandemic to endemic

We presented the webinar COVID-19 lessons from pandemic to endemic. During this webinar Prof. Jerome H. Kim, Director General of the International Vaccine Institute (IVI), discussed: - Pandemic preparedness – lessons learned - Clinical Devel...

Speakers: Leyla Kragten-Tabatabaie

Promising phase 2B trial results of Lanifibranor in NASH

During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (p...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

Insulin Resistance in NAFLD

This webinar focussed on the close multilevel links between insulin resistance/T2DM and NAFLD. Topics that are discussed: Epidemiological links between NAFLD, insulin resistance and T2DM Insulin resistance as root cause of NAFLD: mechan...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

Download

"*" indicates required fields

*

Request for proposal

"*" indicates required fields

*
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn